DCGI approves commercial launch of Tata Group's low-cost COVID-19 test 'Feluda'

This test uses an indigenously-developed, cutting-edge CRISPR technology for detecting the virus' genome sequence

Press Trust of India September 20, 2020 17:32:12 IST
DCGI approves commercial launch of Tata Group's low-cost COVID-19 test 'Feluda'

Representational image. AFP

New Delhi: The Drugs Controller General of India (DGCI) has approved the commercial launch of 'Feluda', the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) said on Saturday.

This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement.

"The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use," the statement added.

CRISPR is a genome editing technology to diagnose diseases. The technology has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology).

"The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from DCGI for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96 per cent sensitivity and 98 percent specificity for detecting novel coronavirus," the statement said.

The Tata CRISPR test is the world's first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing COVID-19, it said.

Moreover, CRISPR is a "futuristic" technology that can also be configured for detection of multiple other pathogens in the future.

"The Tata Group has worked closely with CSIR-IGIB and ICMR to create a high-quality test that will help the nation ramp up COVID-19 testing quickly and economically, with a 'Made in India' product that is safe, reliable, affordable and accessible," the statement added.

Commenting on the development, Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd said, "The approval for the Tata CRISPR test for COVID-19 will give a boost to the country's efforts in fighting the global pandemic.

"The commercialisation of Tata CRISPR test reflects the tremendous R&D talent in the country which can collaborate to transform India's contributions to the global healthcare and scientific research world," he said.

Anurag Agrawal, director, CSIR-IGIB, said the work started by CSIR under the sickle cell mission for genome diagnostics and therapeutics led to new knowledge that could be harnessed to quickly develop new diagnostic test for SARS-CoV-2.

He emphasised that this shows the interconnectedness of scientific knowledge and technology and the innovation of the young research team led by Debojyoti Chakraborty and Souvik Maiti.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

With 63,509 new infections, India's COVID-19 tally over 72.39 lakh; recovery rate at 87%
India

With 63,509 new infections, India's COVID-19 tally over 72.39 lakh; recovery rate at 87%

For six days in a row the active cases of COVID-19 remained below 9 lakh, comprising 11.42 percent of the total caseload, said the health ministry

COVID-19 nasopharyngeal swab: Correct sampling technique is important to prevent injuries and complications
Health

COVID-19 nasopharyngeal swab: Correct sampling technique is important to prevent injuries and complications

Right sampling technique is essential in yielding a good positivity rate and at the same time, one must be careful in not inducing trauma to the surrounding structures

At least 48% of COVID-19 deaths from 25 districts in 8 states, 15 in Maharashtra alone, says health ministry
India

At least 48% of COVID-19 deaths from 25 districts in 8 states, 15 in Maharashtra alone, says health ministry

Ten states, including Maharashtra, Karnataka, Kerala, Tamil Nadu and UP, account for 77% of the active COVID-19 cases, said Health Secretary Rajesh Bhushan